查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864308

马匹保健市场按产品类型、最终用户、疾病和给药途径划分－2025-2032年全球预测

Equine Healthcare Market by Product Type, End User, Disease Indication, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，马匹保健市场将成长至 58.3 亿美元，复合年增长率为 6.73%。

关键市场统计数据
基准年 2024 34.6亿美元
预计年份：2025年 37亿美元
预测年份 2032 58.3亿美元
复合年增长率 (%) 6.73%

一套权威的当代马匹健康照护优先事项框架，强调预防、诊断整合和协作式临床创新。

马匹医疗保健领域正在经历一场变革。临床需求、马主期望和技术发展趋势的交汇，正在重塑医疗保健服务和产品开发的优先事项。人们越来越重视预防和健康维护，并且更加关注能够早期发现疾病的诊断技术，以及支持马匹长期运动能力和生活品质的治疗方法。因此，从临床医生到马主，相关人员都在调整他们的诊疗实践和筹资策略，以体现更积极主动的马匹医疗保健管理模式。

从被动治疗模式转向预防性护理模式的转变，需要建立新的工作流程，增加对监测和诊断技术的投资，并加强兽医、研发机构和产品开发人员之间的合作。这项转变的驱动力在于人们对治疗效果的期望不断提高，对循证干预措施的需求日益增长，以及能够实现远端监测和数据驱动决策的数位化工具的普及。因此，该领域的机构必须将传统的临床方法与创新技术结合，以期提高检测率，标靶治疗，并显着改善动物福利。

鑑于这些趋势，策略倡议应强调临床、商业和马主等相关利益者之间的合作。明确的目标以及务实的试点和推广新技术的路径将决定哪些创新能够成功。最终，马匹医疗保健领域正朝着更整合、数据主导的模式发展，该模式强调合作、严格检验以及对动物长期福利的明确关注。

技术进步、不断变化的照护模式以及马主的期望如何融合，重新定义马匹医疗保健服务和产品创新？

在科技的日趋成熟、疾病管理理念的演变以及相关人员行为的改变的推动下，马匹医疗保健领域正经历着一场变革。先进的影像技术和照护现场技术正在降低诊断的不确定性，缩短干预时间；而穿戴式监测平台则能够实现持续的数据收集，并支持制定个人化的护理方案。同时，治疗方法也不断多样化，标靶药物和旨在促进康復和提升运动表现的专用饲料补充剂的出现，拓展了临床医生和马主可选择的治疗途径。

远端医疗、远端监测和基于订阅的健康计划。这些运作方式的改变促使宠物主人对透明度、便利性和可衡量的结果提出更高的要求，从而加速了能够提供即时资讯和显着益处的服务的普及。研究机构也积极回应，优先进行转化研究，以检验诊断工具和治疗方法，从而在临床实践和科学研究之间建立起回馈机制。

此外，监管思维和供应链韧性正在影响产品策略，促使製造商投资配方稳定性、低温运输物流和简化给药途径。这些趋势并非孤立存在，而是相互促进，共同建构了一个互联互通、灵活敏捷的生态系统，在这个系统中，那些展现价值和易用性的创新最有可能实现规模化发展。

评估近期贸易政策变化对马匹医疗保健产业采购、供应和物流优先事项的重塑及其对营运和供应链的影响。

美国近期关税调整为马匹医疗保健产业的供应链、筹资策略和产品生命週期规划带来了许多复杂影响。进口零件和成品关税的提高迫使製造商和经销商重新评估供应商关係，尽可能优先考虑在地采购，并调整物流结构以维持利润率和供应的连续性。这些调整对医疗设备、诊断设备和某些药品的供应、前置作业时间和成本结构都产生了实际的影响。

为此，许多相关人员正在寻求采购多元化策略，以降低依赖单一供应商的风险。製造商正在探索替代生产基地和双重采购安排，而经销商和大型兽医诊所则在加强库存计划和安全库存政策，以应对交货週期的波动。同时，契约製造和国内供应商也发现，客户对可靠的跨境运输替代方案的需求日益增长，这促使业界重新评估议价动态和生产力计画。

在采购决策中，监管合规性和标籤要求的重要性日益凸显，因为产品在复杂的海关係统中流动时可能面临额外的审查和延误。因此，采购部门正在投入更多资源用于海关专业知识和供应商审核，而研究机构和临床医生则优先考虑那些供应链韧性已得到验证的产品。这些因素共同造就了一个在不断变化的贸易政策面前，更加重视透明度、冗余性和灵活性的市场。

全面的細項分析，将产品类型、最终用户、疾病适应症和给药途径映射到策略创新和商业化路径。

有效的细分框架能够揭示产品类型、最终用户、疾病适应症和给药途径等因素交汇处的创新与需求，从而提供有针对性的开发和商业化蓝图。就产品类型而言，市场涵盖医疗设备、诊断试剂、饲料添加剂、药品和疫苗。在医疗设备领域，存在着许多机会，例如支持持续评估的监测设备、用于治疗骨骼和关节疾病的整形外科器械以及能够实现高级手术干预的外科器械。在诊断试剂领域，存在着许多机会，例如成像技术、实验室分析方法以及能够支援临床现场快速决策的照护现场技术。饲料添加剂分为矿物质、营养素和维生素製剂，旨在支持系统健康和恢復。药品包括抗发炎药、抗寄生虫药、抗生素和荷尔蒙。在抗发炎药物中，皮质类固醇和非类固醇消炎剂(NSAIDs) 是主要的治疗选择，而抗寄生虫药则分为体外寄生虫药和体内寄生虫药。与马匹照护相关的抗生素类别包括β-内酰胺类、大环内酯类和四环霉素。激素分为生长促进剂和生殖促进剂。疫苗有灭活疫苗、减毒活病毒疫苗和重组疫苗三种形式，每种疫苗的储存和给药方式都有其独特的注意事项。

从终端用户的观点来看，该生态系统由马主、线上药局、研究机构和兽医诊所组成。马主分为养殖场和个别马主，其管理规模和预防保健的投资重点各不相同。线上药局透过非处方药和处方药管道运营，提供便利和丰富的选择，但也需要谨慎的临床管理。研究机构的特点是既有促进创新和检验的公立机构，也有私立机构；兽医诊所则涵盖大型综合动物医院和专注于个人化护理的私人诊所。疾病适应症的细分同样突显了临床需求和产品相关性：胃肠道疾病，如腹痛、腹泻和溃疡，需要快速诊断和支持治疗；感染疾病，分为细菌性、寄生虫性和病毒性，需要综合的预防和治疗策略；肌肉骨骼疾病，包括关节疾病、整形外科损伤和软组织损伤，则受益于康復和药物治疗相结合的方法。子宫内膜炎和不孕症等生殖系统疾病需要相应的治疗和诊断方案。呼吸系统疾病分为下呼吸道疾病和上呼吸道疾病，每种疾病都需要特定的给药途径和支持性照护方案。

考虑给药途径有助于了解吸入、注射、口服和外用等不同给药途径的研发和应用趋势。吸入途径包括干粉吸入和雾化吸入，两者均适用于标靶呼吸系统介入。注射途径包括肌肉注射、静脉注射和皮下注射，这些途径会影响起效时间和给药策略。口服途径包括液体、粉末和片剂，其主要特点是便于居家照护。外用疗法，包括乳膏、凝胶和喷雾剂，可实现局部治疗，同时最大限度地减少全身暴露。对这些细分维度的全面了解，有助于研发人员和临床医生更好地确定投资优先级，并根据每个用户群体和适应症的具体需求和限制定制产品。

区域差异和战略机会（美洲、欧洲、中东和非洲、亚太地区）对打入市场策略和研发优先事项具有重要意义。

区域趋势影响投资领域、研究重点和应用方向。了解这些差异对于市场准入和伙伴关係决策至关重要。在美洲，先进的临床基础设施、积极的饲主参与以及对伴侣动物和竞技马匹的重视，共同推动了对先进诊断技术、专业治疗方法和综合护理模式的需求。该地区优先考虑循证治疗方法，并率先采用远距监测和远端保健服务，从而在某些领域推动了医疗保健的优质化。

儘管欧洲、中东和非洲地区（EMEA）的法规环境和兽医实践规范存在显着差异，但该地区正朝着统一的护理标准稳步迈进，尤其是在感染疾病监测和疫苗策略方面。该地区部分地区的公私合营和强大的研究网络正在促进多中心合作和转化研究，而其他市场则更注重成本效益高的配方和适用于不同实践环境的实用通讯协定。

亚太地区正经历临床快速现代化、中产阶级拥有运动和休閒马匹人数不断增长以及对本地生产能力日益重视等多重挑战。整个地区不断增长的需求往往推动着对国内研发和生产的定向投资，同时法律规范也在不断改进，以适应更广泛的诊断和治疗产品。整体而言，每个区域丛集都面临独特的机会和挑战，优先制定能够兼顾临床实践模式、法律规范和当地供应链实际情况的区域策略，将带来最永续的成果。

竞争评估着重于证据产生、供应链敏捷性和策略伙伴关係关係，以推动差异化和市场接受度。

马匹医疗保健领域的竞争格局由成熟的动物用药品製造商、专业医疗器材和诊断公司、兽医分销网络以及专注于小众疗法和数位监测的敏捷型新兴企业组成。现有企业往往在多个产品类型中维持业务布局，利用规模经济、监管经验和广泛的分销网络。同时，专业公司凭藉着深厚的临床洞察力、专业的科技平台以及与兽医的紧密合作，获得竞争优势。新参与企业则可望透过数位化工具、照护现场诊断和配方创新，降低使用门槛并提高饲主参与度，从而颠覆现有格局。

设备製造商与诊断开发商之间的合作日益增多，从而能够提供集监测、数据分析和治疗建议于一体的综合解决方案。此外，产学合作正在加速转化研究，以检验新型治疗方法在临床环境中的有效性。通路也至关重要，线上药局和专业兽药经销商影响着产品的认知度和可及性，而大型动物医院和独立诊所则基于产品在实际应用中的表现以及与临床工作流程的整合便捷性，影响着临床应用。

智慧财产权、监管经验和生产弹性是企业竞争优势的关键。能够提供经证实的临床疗效、高效管理以及对医疗专业人员的强力支持的企业更有可能获得市场优势。最终，在复杂且以临床主导的市场中，那些注重证据产生、供应链可靠性和客製化商业性合作的企业策略最有可能取得成功。

切实可行的策略性倡议，旨在帮助产业领导者增强韧性、进行创新临床检验，并透过整合的商业性模式加速产品应用。

产业领导者应优先考虑一系列切实可行的措施，以平衡短期营运韧性与长期创新和实证研究。首先，他们需要投资供应链的透明度和冗余性，以减轻贸易政策变化和零件短缺对营运的影响。与多家合格供应商建立合作关係并加强物流规划，可以在维持品质标准的同时降低中断风险。

第二，加速结合诊断和治疗的临床检验项目，以展示真实世界的临床疗效。进行涉及兽医诊所和研究机构的严谨转化研究，有助于建立医疗专业人员的信任，并促进技术的广泛应用。第三，透过实施监测平台和远端医疗工作流程，促进数位整合。这将提高医疗服务的连续性，并透过数据驱动的洞见创造价值。这些工具的设计应确保与现有临床系统无缝集成，并易于使用。

第四，透过认识到养殖场和个别养殖户之间的差异，并制定优先考虑合规性和实用性的通路策略，从而调整商业性策略以适应不同的终端用户群体。第五，探索策略联盟，将医疗设备、诊断和製药领域的互补优势结合起来，以提供贯穿临床路径的综合解决方案。最后，追求卓越的监管事务和合规性，以确保加快核准和持续的市场进入。这些努力共同构成了一条切实可行的蓝图，既能推动业务永续营运，又能产生临床影响。

本报告采用严谨的多方法研究框架，整合了关键相关人员的见解、监管审查和跨细分市场分析，从而得出可操作的结论。

本报告的研究融合了多种定性和定量方法，以确保得出可靠且可操作的见解。主要研究包括对兽医、实验室技术人员、行业高管和马主进行结构化访谈，以收集关于临床需求、推广障碍和产品性能的不同观点。次要研究则查阅了同行评审文献、监管指南、技术标准和公共文件，以建立基于检验资讯来源的观察结果，并分析区域差异。

分析采用交叉细分映射法，识别产品类型、最终用户、疾病适应症和给药途径与未满足需求交叉的领域。供应链和贸易政策分析利用海关数据、物流绩效指标和官方贸易通报来评估营运脆弱性。竞争格局分析结合专利申请、产品註册资讯和临床试验註册信息，评估创新路径和差异化策略。在整个研究过程中，方法论强调证据三角验证、迭代同侪检验以及对区域监管和实践差异的考虑。

这种多层次的调查方法确保结论有观察到的实践和已记录的证据支持，同时又能对新兴趋势保持敏锐的洞察力。在原始资料有限的情况下，研究结果会受到质疑并进行交叉检验，以维护分析的完整性；所提出的建议也力求实用，并能在各种组织环境中实施。

全面探讨临床检验、互通性和健全的治理将如何决定马匹医疗保健的未来成功。

总之，在技术进步、护理模式变革以及马主和临床医生日益增长的期望的推动下，马匹医疗保健产业正经历着显着的变革。这些因素为那些具有明确临床价值、易于融入临床实践且拥有稳健供应链的解决方案创造了机会。能够将严格的临床检验与切实可行的商业化策略相结合，同时又能应对当地监管和营运现实的机构，将更有可能取得成功。

展望未来，相关人员专注于投资转化研究、优先考虑诊断和治疗互通性，并透过使用者友善平台与马主互动的利害关係人将获得竞争优势。此外，那些透过多元化采购和完善的物流计划积极应对供应链和政策风险的组织，将更有能力在瞬息万变的贸易环境中维持营运。最终，最具影响力的创新将源于连结研究、临床实践和产品开发的合作，从而产生能够显着改善马匹福利和表现的干预措施。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将穿戴式生物感测器与远端医疗平台结合，用于持续监测马匹健康状况
  • 利用基因组分析进行马匹疾病预防与治疗的精准医疗方法
  • 利用干细胞和富血小板血浆拓展再生医学在马整形外科的应用
  • 开发针对感染疾病感染疾病和通用病威胁的新型马疫苗
  • 引入数位化记录和数据分析，以优化马匹的运动表现和福祉。
  • 市场对天然草药补充剂的需求日益增长，这些补充剂可用于改善马匹肠道健康和代谢紊乱。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的马匹保健市场

  • 医疗设备
    • 监测
    • 整形外科
    • 手术器械
  • 诊断试剂
    • 影像诊断
    • 考场
    • 护理点
  • 饲料添加剂
    • 矿物质补充剂
    • 营养补充品
    • 维生素补充剂
  • 製药
    • 抗发炎药
      • 皮质类固醇
      • 非类固醇消炎剂
    • 抗寄生虫药物
      • 体外寄生虫杀灭剂
      • 体内杀寄生虫剂
    • 抗生素
      • β-内酰胺类
      • 大环内酯类
      • 四环霉素
    • 荷尔蒙
      • 生长促进剂
      • 生殖
  • 疫苗
    • 失活
    • 活病毒疫苗
    • 重组

9. 按最终用户分類的马匹保健市场

  • 马主
    • 养殖场
    • 个人所有者
  • 网路药房
    • OTC
    • 处方药
  • 研究所
    • 私人的
    • 公共
  • 兽医诊所
    • 大型动物医院
    • 私人诊所

10. 按疾病指征分類的马匹保健市场

  • 消化系统疾病
    • 绞痛
    • 腹泻
    • 溃疡
  • 感染疾病
    • 细菌
    • 寄生
    • 病毒性的
  • 肌肉骨骼疾病
    • 关节疾病
    • 整形外科损伤
    • 软组织损伤
  • 生殖疾病
    • 子宫内膜炎
    • 不孕症
  • 呼吸系统疾病
    • 下呼吸道
    • 上呼吸道

11. 依给药途径分類的马匹保健市场

  • 吸入
    • 干粉
    • 雾化
  • 注射
    • 肌肉内注射
    • 静脉注射
    • 皮下注射
  • 口服
    • 液体
    • 粉末
    • 药片
  • 外用药物
    • 奶油
    • 凝胶
    • 喷

第十二章：各地区的马匹保健市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按群体分類的马匹保健市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国马匹保健市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim GmbH
    • Elanco Animal Health Incorporated
    • Ceva Sante Animale SA
    • Virbac SA
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • Bimeda, Inc.
    • Norbrook Laboratories Limited
Product Code: MRR-3F223D52475E

The Equine Healthcare Market is projected to grow by USD 5.83 billion at a CAGR of 6.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.46 billion
Estimated Year [2025] USD 3.70 billion
Forecast Year [2032] USD 5.83 billion
CAGR (%) 6.73%

An authoritative framing of contemporary equine healthcare priorities emphasizing prevention, diagnostic integration, and collaborative clinical innovation

The equine healthcare landscape is at an inflection point where clinical imperatives, owner expectations, and technological capabilities converge to reshape priorities across care delivery and product development. Prevention and wellness are increasingly central, with growing emphasis on diagnostics that enable early detection and on therapeutics that support long-term performance and quality of life. As a result, stakeholders from clinicians to owners are adapting practices and procurement strategies to reflect a more proactive model of equine health management.

Transitioning from a reactive model toward preventive care requires new workflows, investments in monitoring and diagnostics, and greater collaboration between veterinary practitioners, research laboratories, and product developers. These shifts are driven by rising expectations for outcomes, the need for evidence-based interventions, and the broader availability of digital tools that permit remote monitoring and data-driven decision-making. Consequently, organizations operating within this space must reconcile traditional clinical approaches with innovations that promise improved detection, targeted therapies, and measurable welfare gains.

Given these dynamics, the opening of any strategic initiative should emphasize alignment across clinical, commercial, and owner constituencies. Clarity of purpose, coupled with pragmatic pathways for piloting and scaling new technologies, will determine which innovations achieve traction. Ultimately, the equine healthcare sector is moving toward a more integrated, data-informed paradigm that rewards collaboration, rigorous validation, and a clear orientation toward long-term animal welfare.

How technological advances, shifting care delivery models, and owner expectations are coalescing to redefine equine healthcare delivery and product innovation

The equine healthcare environment is experiencing transformative shifts driven by technological maturation, evolving disease management philosophies, and changes in stakeholder behavior. Advanced imaging and point-of-care diagnostics are reducing diagnostic uncertainty and shortening time to intervention, while wearable monitoring platforms are enabling continuous data capture that supports individualized care plans. At the same time, therapeutics are diversifying with targeted pharmaceuticals and specialized feed supplements designed to support recovery and performance, thereby broadening treatment pathways available to clinicians and owners alike.

Concurrently, veterinary practices are adapting to new revenue and care models that emphasize telemedicine, remote monitoring, and subscription-based wellness programs. These operational shifts are accompanied by enhanced expectations from owners for transparency, convenience, and measurable outcomes, which in turn accelerate adoption of services that deliver real-time insights and demonstrable benefits. Research laboratories are responding by prioritizing translational studies that validate diagnostic tools and therapeutic regimens, creating a feedback loop between clinical practice and scientific investigation.

Moreover, regulatory thinking and supply chain resilience are influencing product strategies, prompting manufacturers to invest in formulation stability, cold-chain logistics, and simplified administration routes. Taken together, these trends are not isolated; rather, they reinforce one another to create a more interconnected and agile ecosystem where innovations that demonstrate value and ease of use are most likely to scale.

Assessing the operational and supply chain consequences of recent trade policy shifts that are reshaping procurement, sourcing, and logistics priorities across equine healthcare

Recent tariff changes in the United States have introduced a layer of complexity that affects supply chains, sourcing strategies, and product lifecycle planning across the equine healthcare sector. Increased duties on imported components and finished products have prompted manufacturers and distributors to reassess supplier relationships, prioritize local sourcing where feasible, and reconfigure logistics to preserve margin and continuity of supply. These adjustments have practical implications for the availability, lead times, and cost structure of devices, diagnostics, and select pharmaceutical products.

In response, many stakeholders have pursued diversification strategies to mitigate exposure to single-source dependencies. Manufacturers are exploring alternative manufacturing bases and dual-sourcing arrangements, while distributors and large veterinary practices are intensifying inventory planning and safety stock policies to offset lead-time volatility. At the same time, contract manufacturers and domestic suppliers are experiencing increased interest from clients seeking reliable alternatives to cross-border shipments, which reshapes negotiation dynamics and capacity planning within the industry.

Regulatory compliance and labeling requirements have also become more salient in procurement decisions, as products that must transit complex customs regimes can face additional scrutiny and delay. Consequently, procurement teams are allocating more resources to customs expertise and supplier qualification, while research laboratories and clinicians are prioritizing products whose supply chains offer demonstrable resilience. The combined effect is a market that values transparency, redundancy, and flexibility in the face of evolving trade policies.

Comprehensive segmentation analysis mapping product types, end users, disease indications, and administration routes to strategic innovation and commercial pathways

An effective segmentation framework reveals where innovation and demand intersect across product types, end users, disease indications, and routes of administration, providing a roadmap for targeted development and commercialization. When exploring product type, the landscape encompasses devices, diagnostics, feed supplements, pharmaceuticals, and vaccines. Within devices there are opportunities in monitoring devices that support continuous assessment, orthopedic instruments that address bone and joint conditions, and surgical instruments that enable advanced interventions. Diagnostics span imaging modalities, laboratory-based assays, and point-of-care technologies that bring faster decision-making into clinical contexts. Feed supplements divide into mineral, nutritional, and vitamin formulations that support systemic health and recovery. Pharmaceuticals include anti-inflammatories, anti-parasitic agents, antibiotics, and hormones; within anti-inflammatories the categories of corticosteroids and nonsteroidal anti-inflammatory drugs shape therapeutic choice, while anti-parasitic solutions encompass ectoparasiticides and endoparasiticides. Antibiotic classes relevant to equine care include beta lactams, macrolides, and tetracyclines, and hormones are differentiated by growth- versus reproductive-focused agents. Vaccines are offered in inactivated, live attenuated, and recombinant formats, each with distinct storage and administration considerations.

From an end user perspective, the ecosystem includes equine owners, online pharmacies, research laboratories, and veterinary practices. Equine owners are comprised of breeding farms and individual owners who have differing priorities around management scale and investment in preventive care. Online pharmacies operate across over-the-counter and prescription channels, providing convenience and range but requiring careful clinical oversight. Research laboratories are characterized by private and public institutions that drive innovation and validation, whereas veterinary practices range from large animal hospitals with integrated services to private practices focused on personalized care. Disease indication segmentation likewise highlights areas of clinical need and product alignment: digestive disorders such as colic, diarrhea, and ulcers demand rapid diagnostic and supportive care; infectious diseases categorized as bacterial, parasitic, and viral require integrated prevention and treatment strategies; musculoskeletal disorders covering joint disorders, orthopedic injuries, and soft tissue injuries benefit from combined rehabilitative and pharmaceutical approaches; reproductive disorders including endometritis and infertility intersect with both therapeutic and diagnostic solutions; respiratory disorders divided into lower and upper respiratory conditions necessitate specific administration routes and supportive care plans.

Considering route of administration clarifies development and adoption dynamics across inhalation, injectable, oral, and topical options. Inhalation approaches include dry powder delivery and nebulization, both suited for targeted respiratory interventions. Injectable formats encompass intramuscular, intravenous, and subcutaneous routes that influence onset and dosing strategies. Oral delivery consists of liquids, powders, and tablets that prioritize ease of administration for at-home care scenarios. Topical therapies in creams, gels, and sprays enable localized treatment with minimal systemic exposure. By mapping these segmentation dimensions together, developers and clinicians can better prioritize investments and tailor offerings to the specific needs and constraints of each user group and indication.

Regional differentiation and strategic opportunities across the Americas, Europe Middle East and Africa, and Asia Pacific that inform go to market and R D prioritization

Regional dynamics shape where investment, research emphasis, and adoption are most pronounced, and understanding these differences is essential for market entry and partnership decisions. In the Americas, a combination of advanced clinical infrastructure, strong owner engagement, and a thriving companion and performance equine culture drives demand for diagnostic sophistication, specialized therapeutics, and integrated care models. This region prioritizes high-evidence interventions and shows early adoption for remote monitoring and telehealth-enabled services, which supports a premiumization of care in certain segments.

Within the Europe, Middle East & Africa cluster, variability is pronounced across regulatory environments and veterinary practice norms, yet there is consistent momentum toward harmonized standards of care, particularly for infectious disease surveillance and vaccination strategies. Public-private collaboration and strong research networks in parts of this region are facilitating multicenter studies and translational research, while some markets emphasize cost-effective formulations and pragmatic protocols suited to diverse practice settings.

Asia-Pacific presents a mix of rapid clinical modernization, expanding middle-class ownership of performance and leisure horses, and an increasing focus on local manufacturing capability. In this region, demand growth is often accompanied by targeted investments in domestic research and production, and regulatory pathways continue to evolve to accommodate a broader array of diagnostics and therapeutics. Taken together, each geographic cluster offers distinct opportunities and constraints, so prioritizing regional strategies that account for clinical practice patterns, regulatory frameworks, and local supply chain realities will yield the most sustainable outcomes.

An assessment of competitive dynamics emphasizing evidence generation, supply chain agility, and strategic partnerships that drive differentiation and adoption

Competitive dynamics in equine healthcare are defined by a mix of established animal health manufacturers, specialist device and diagnostics firms, veterinary distribution networks, and agile start-ups focused on niche therapeutics or digital monitoring. Established players tend to leverage scale, regulatory experience, and broad distribution to maintain presence across multiple product categories, while specialist firms compete on deep clinical expertise, targeted technology platforms, and close alignment with veterinary practitioners. New entrants bring disruptive potential through digital tools, point-of-care diagnostics, and formulation innovations that lower barriers to use and enhance owner engagement.

Partnerships between device makers and diagnostic developers are increasingly common, enabling integrated solutions that combine monitoring, data analytics, and therapeutic recommendations. Additionally, collaborations between research laboratories and industry are accelerating translational work that validates new interventions under clinical conditions. Distribution channels also matter: online pharmacies and specialized veterinary distributors influence product visibility and access, while large animal hospitals and private practices shape clinical adoption based on real-world performance and ease of integration into care pathways.

Intellectual property, regulatory experience, and manufacturing agility are differentiators that influence competitive positioning. Firms that can demonstrate clinical outcomes, streamline administration, and provide robust support for practitioners will be better positioned to capture preference. Ultimately, company strategies that emphasize evidence generation, supply chain reliability, and tailored commercial engagement are most likely to succeed in a complex and clinically driven market.

Practical strategic initiatives for industry leaders to strengthen resilience, validate innovations clinically, and accelerate adoption through integrated commercial approaches

Industry leaders should prioritize a set of actionable initiatives that balance near-term operational resilience with longer-term innovation and evidence development. First, invest in supply chain transparency and redundancy to mitigate the operational impacts of trade policy shifts and component scarcity. By fostering relationships with multiple qualified suppliers and strengthening logistics planning, organizations can reduce disruption risk while maintaining quality standards.

Second, accelerate clinical validation programs that pair diagnostics with therapeutics to demonstrate real-world outcomes. Rigorous, translational studies that engage veterinary practices and research laboratories will unlock practitioner confidence and facilitate broader adoption. Third, embrace digital integration by deploying monitoring platforms and telemedicine workflows that improve continuity of care and create value through data-driven insights. These tools should be designed for ease of use and seamless integration into existing clinical systems.

Fourth, tailor commercial approaches to end-user segments by recognizing differences between breeding farms and individual owners, and by developing route-of-administration strategies that prioritize adherence and practicality. Fifth, explore strategic alliances that combine complementary strengths across device, diagnostic, and pharmaceutical domains to deliver bundled offerings aligned with clinical pathways. Finally, commit to regulatory and compliance excellence to expedite approvals and ensure consistent market access. Together, these actions provide a pragmatic roadmap for advancing both business resilience and clinical impact.

A rigorous multi-method research framework combining primary stakeholder insights, regulatory review, and cross segmentation analysis to support actionable conclusions

The research underpinning this report synthesizes multiple qualitative and quantitative approaches to ensure robust, actionable findings. Primary research included structured interviews with veterinary practitioners, laboratory scientists, industry executives, and equine owners to capture diverse perspectives on clinical needs, adoption barriers, and product performance. Secondary research involved a careful review of peer-reviewed literature, regulatory guidance, technical standards, and public policy documents to ground observations in validated sources and to contextualize regional differences.

Analytical methods incorporated cross-segmentation mapping to identify where product types, end users, disease indications, and routes of administration intersect with unmet needs. Supply chain and trade policy analyses were conducted using customs data, logistics performance indicators, and public trade notices to assess operational vulnerabilities. Competitive landscape analysis combined patent filings, product registries, and clinical trial registries to evaluate innovation trajectories and differentiation strategies. Throughout the study, methods emphasized triangulation of evidence, iterative validation with subject-matter experts, and sensitivity to regional regulatory and practice variations.

This layered methodology ensures conclusions are grounded in observed practice and documented evidence while remaining sensitive to emerging trends. Where primary data were limited, findings were qualified and cross-checked to preserve analytic integrity, and recommendations were formulated to be pragmatic and implementable across a range of organizational contexts.

Synthesis and forward looking perspective on how clinical validation, interoperability, and resilient operations will determine future success in equine healthcare

In closing, the equine healthcare sector is undergoing meaningful evolution driven by technological advances, shifting care models, and heightened expectations from owners and clinicians. These forces are creating opportunities for solutions that deliver clear clinical value, are easy to integrate into practice, and exhibit resilient supply chains. Success will favor organizations that can marry rigorous clinical validation with pragmatic commercialization strategies, while also demonstrating responsiveness to regional regulatory and operational realities.

Going forward, stakeholders who invest in translational research, prioritize interoperability between diagnostics and therapeutics, and engage owners through user-friendly platforms will secure competitive advantage. Moreover, those who proactively address supply chain and policy risks through diversified sourcing and robust logistics planning will be better equipped to sustain operations in a fluid trade environment. Ultimately, the most impactful advances will emerge from collaborations that bridge research, clinical practice, and product development, producing interventions that meaningfully enhance equine welfare and performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of wearable biosensors and telehealth platforms for continuous equine health monitoring
  • 5.2. Precision medicine approaches using genomic profiling for equine disease prevention and treatment
  • 5.3. Expansion of regenerative therapies using stem cells and platelet rich plasma in equine orthopedics
  • 5.4. Development of novel equine vaccines targeting emerging infectious diseases and zoonotic threats
  • 5.5. Adoption of digital recordkeeping and data analytics for optimizing equine performance and welfare
  • 5.6. Rising demand for natural and herbal supplements addressing equine gut health and metabolic disorders

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Equine Healthcare Market, by Product Type

  • 8.1. Devices
    • 8.1.1. Monitoring
    • 8.1.2. Orthopedic
    • 8.1.3. Surgical Instruments
  • 8.2. Diagnostics
    • 8.2.1. Imaging
    • 8.2.2. Laboratory
    • 8.2.3. Point Of Care
  • 8.3. Feed Supplements
    • 8.3.1. Mineral Supplements
    • 8.3.2. Nutritional Supplements
    • 8.3.3. Vitamin Supplements
  • 8.4. Pharmaceuticals
    • 8.4.1. Anti-Inflammatories
      • 8.4.1.1. Corticosteroids
      • 8.4.1.2. NSAIDs
    • 8.4.2. Anti-Parasitic
      • 8.4.2.1. Ectoparasiticides
      • 8.4.2.2. Endoparasiticides
    • 8.4.3. Antibiotics
      • 8.4.3.1. Beta Lactams
      • 8.4.3.2. Macrolides
      • 8.4.3.3. Tetracyclines
    • 8.4.4. Hormones
      • 8.4.4.1. Growth
      • 8.4.4.2. Reproductive
  • 8.5. Vaccines
    • 8.5.1. Inactivated
    • 8.5.2. Live Attenuated
    • 8.5.3. Recombinant

9. Equine Healthcare Market, by End User

  • 9.1. Equine Owners
    • 9.1.1. Breeding Farms
    • 9.1.2. Individual Owners
  • 9.2. Online Pharmacies
    • 9.2.1. OTC
    • 9.2.2. Prescription
  • 9.3. Research Laboratories
    • 9.3.1. Private
    • 9.3.2. Public
  • 9.4. Veterinary Practices
    • 9.4.1. Large Animal Hospitals
    • 9.4.2. Private Practices

10. Equine Healthcare Market, by Disease Indication

  • 10.1. Digestive Disorders
    • 10.1.1. Colic
    • 10.1.2. Diarrhea
    • 10.1.3. Ulcers
  • 10.2. Infectious Diseases
    • 10.2.1. Bacterial
    • 10.2.2. Parasitic
    • 10.2.3. Viral
  • 10.3. Musculoskeletal Disorders
    • 10.3.1. Joint Disorders
    • 10.3.2. Orthopedic Injuries
    • 10.3.3. Soft Tissue Injuries
  • 10.4. Reproductive Disorders
    • 10.4.1. Endometritis
    • 10.4.2. Infertility
  • 10.5. Respiratory Disorders
    • 10.5.1. Lower Respiratory
    • 10.5.2. Upper Respiratory

11. Equine Healthcare Market, by Route Of Administration

  • 11.1. Inhalation
    • 11.1.1. Dry Powder
    • 11.1.2. Nebulization
  • 11.2. Injectable
    • 11.2.1. Intramuscular
    • 11.2.2. Intravenous
    • 11.2.3. Subcutaneous
  • 11.3. Oral
    • 11.3.1. Liquids
    • 11.3.2. Powders
    • 11.3.3. Tablets
  • 11.4. Topical
    • 11.4.1. Creams
    • 11.4.2. Gels
    • 11.4.3. Sprays

12. Equine Healthcare Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Equine Healthcare Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Equine Healthcare Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Merck & Co., Inc.
    • 15.3.3. Boehringer Ingelheim GmbH
    • 15.3.4. Elanco Animal Health Incorporated
    • 15.3.5. Ceva Sante Animale S.A.
    • 15.3.6. Virbac S.A.
    • 15.3.7. Vetoquinol S.A.
    • 15.3.8. Dechra Pharmaceuticals PLC
    • 15.3.9. Bimeda, Inc.
    • 15.3.10. Norbrook Laboratories Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL EQUINE HEALTHCARE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA EQUINE HEALTHCARE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. EQUINE HEALTHCARE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. EQUINE HEALTHCARE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. EQUINE HEALTHCARE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL EQUINE HEALTHCARE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL EQUINE HEALTHCARE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 327. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 328. GLOBAL EQUINE HEALTHCARE M